Predicting treatment for neonatal abstinence syndrome in infants born to women maintained on opioid agonist medication.

ABSTRACT:

Aim

To identify factors that predict the expression of neonatal abstinence syndrome (NAS) in infants exposed to methadone or buprenorphine in utero.

Design and setting

Multi-site randomized clinical trial in which infants were observed for a minimum of 10 days following birth, and assessed for NAS symptoms by trained raters.

Participants

A total of 131 infants born to opioid dependent mothers, 129 of whom were available for NAS assessment.

Measurements

Generalized linear modeling was performed using maternal and infant characteristics to predict: peak NAS score prior to treatment, whether an infant required NAS treatment, length of NAS treatment and total dose of morphine required for treatment of NAS symptoms.

Findings

Of the sample, 53% (68 infants) re

SUBMITTER: Kaltenbach K 

PROVIDER: S-EPMC4268864 | biostudies-literature | 2012 Nov

REPOSITORIES: biostudies-literature